Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Oct 9, 2022
Date Accepted: May 23, 2023
Date Submitted to PubMed: May 29, 2023

The final, peer-reviewed published version of this preprint can be found here:

The Kinetics of Anti–SARS-CoV-2 Antibodies in Pediatric Patients and the Characterization of Post–COVID-19 Condition at 6 Months After Infection: Protocol for a Longitudinal Observational Study

Arguni E, Chamida FM, Indrawanti RR, Rusmawatiningtyas D, Dewi YP, Safitri I

The Kinetics of Anti–SARS-CoV-2 Antibodies in Pediatric Patients and the Characterization of Post–COVID-19 Condition at 6 Months After Infection: Protocol for a Longitudinal Observational Study

JMIR Res Protoc 2023;12:e43344

DOI: 10.2196/43344

PMID: 37246961

PMCID: 10246664

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

A Protocol Study: Kinetics of Anti-SARS-CoV-2 antibodies in pediatric patients and Characterization of Long COVID at Six months post-infection

  • Eggi Arguni; 
  • Fatia Murni Chamida; 
  • Rr Ratni Indrawanti; 
  • Desy Rusmawatiningtyas; 
  • Yunika Puspa Dewi; 
  • Ida Safitri

ABSTRACT

Background:

Data regarding kinetics of anti-SARS-CoV-2 antibody and information about Long Covid in children are scarce, even though cases of COVID-19 in children are 18.5% of the total COVID-19 cases in the world with the prevalence of Long COVID is around 4-66%.

Objective:

We aimed to analyse anti RBD IgG antibodies over time and characterize long COVID sign and symptom in pediatric patients at 6 months following infection.

Methods:

This is a longitudinal observational study which was approved by the Medical and Health Research Ethics Committee (MHREC) Faculty of Medicine, Public Health, and Nursing UGM (KE/FK/1288/EC/2021). COVID-19 pediatric patients diagnosed by positive molecular assay in nasopharyngeal swab will be tested for anti SARS-CoV-2 antibodies using the Roche Elecsys anti-SARS-CoV-2 S assay at the time of diagnosis, two weeks, one, three, and six months after diagnosed. Antibody titer data will be reported as mean and standard deviation. The respondents’ signs and symptoms will be observed up to 6 months after the onset of infection. The clinical features will be reported in frequency and percentage.

Results:

The funding was obtained in 2021, with participant enrollment starting in February to April 2022. Results analysis are expected in November 2022

Conclusions:

This can be the first study that reported the kinetics of Anti-SARS-COV-2 antibodies for up to 6 months following infection and long-covid prospectively in the Indonesian pediatric population.


 Citation

Please cite as:

Arguni E, Chamida FM, Indrawanti RR, Rusmawatiningtyas D, Dewi YP, Safitri I

The Kinetics of Anti–SARS-CoV-2 Antibodies in Pediatric Patients and the Characterization of Post–COVID-19 Condition at 6 Months After Infection: Protocol for a Longitudinal Observational Study

JMIR Res Protoc 2023;12:e43344

DOI: 10.2196/43344

PMID: 37246961

PMCID: 10246664

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.

Advertisement